287 related articles for article (PubMed ID: 15784258)
1. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.
Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I
J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258
[TBL] [Abstract][Full Text] [Related]
2. Isolation of scFvs that inhibit the NS3 protease of hepatitis C virus by a combination of phage display and a bacterial genetic screen.
Nahary L; Trahtenherts A; Benhar I
Methods Mol Biol; 2009; 562():115-32. PubMed ID: 19554291
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies.
Zemel R; Berdichevsky Y; Bachmatov L; Benhar I; Tur-Kaspa R
J Hepatol; 2004 Jun; 40(6):1000-7. PubMed ID: 15158342
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hepatitis C virus RNA replicons by peptide aptamers.
Trahtenherts A; Gal-Tanamy M; Zemel R; Bachmatov L; Loewenstein S; Tur-Kaspa R; Benhar I
Antiviral Res; 2008 Mar; 77(3):195-205. PubMed ID: 18243349
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the hepatitis C virus NS3 protease activity by Fv fragment of antibody 8D4.
Kasai N; Tsumoto K; Niwa S; Misawa S; Ueno T; Hayashi H; Kumagai I
Biochem Biophys Res Commun; 2001 Feb; 281(2):416-24. PubMed ID: 11181064
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
Hamill P; Jean F
Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
[TBL] [Abstract][Full Text] [Related]
7. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
8. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
Hahm B; Back SH; Lee TG; Wimmer E; Jang SK
Virology; 1996 Dec; 226(2):318-26. PubMed ID: 8955051
[TBL] [Abstract][Full Text] [Related]
9. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
10. Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein.
Chen M; Sällberg M; Sönnerborg A; Jin L; Birkett A; Peterson D; Weiland O; Milich DR
Hepatology; 1998 Jul; 28(1):219-24. PubMed ID: 9657115
[TBL] [Abstract][Full Text] [Related]
11. A novel high throughput screening assay for HCV NS3 serine protease inhibitors.
Berdichevsky Y; Zemel R; Bachmatov L; Abramovich A; Koren R; Sathiyamoorthy P; Golan-Goldhirsh A; Tur-Kaspa R; Benhar I
J Virol Methods; 2003 Feb; 107(2):245-55. PubMed ID: 12505640
[TBL] [Abstract][Full Text] [Related]
12. [Detection of proteolytic activity of hepatitis C virus NS3-4A protease using enzymelinked immunosorbent assay].
Chen X; Guo J; Chen H; Wanglin
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Jun; 22(3):300-2. PubMed ID: 12903484
[TBL] [Abstract][Full Text] [Related]
13. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
14. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
15. [Preparation of recombinant IL-1 fusion protein as the substrate for HCV NS3 serine protease].
Hu W; Liu W; Song XG; Zhu CX; Ling SG
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jan; 22(1):43-6. PubMed ID: 16388743
[TBL] [Abstract][Full Text] [Related]
16. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK
Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887
[TBL] [Abstract][Full Text] [Related]
17. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.
Chen CS; Chiou CT; Chen GS; Chen SC; Hu CY; Chi WK; Chu YD; Hwang LH; Chen PJ; Chen DS; Liaw SH; Chern JW
J Med Chem; 2009 May; 52(9):2716-23. PubMed ID: 19419203
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.
Gal-Tanamy M; Zemel R; Bachmatov L; Jangra RK; Shapira A; Villanueva RA; Yi M; Lemon SM; Benhar I; Tur-Kaspa R
Antiviral Res; 2010 Oct; 88(1):95-106. PubMed ID: 20705106
[TBL] [Abstract][Full Text] [Related]
19. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
[TBL] [Abstract][Full Text] [Related]
20. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
